Ajay K. Agrawal
Corporate Officer/Principal bei Almac Sciences Group Ltd.
Profil
Dr. Ajay K.
Agrawal is Director-Business Development at Almac Sciences Group Ltd.
and Independent Non-Executive Director at ImmuPharma Plc.
He is on the Board of Directors at Ecron Acunova GmbH and ImmuPharma Plc.
Dr. Agrawal was previously employed as Director-Business Development by Xenetic Biosciences Plc.
He received his doctorate degree from the University of Alberta.
Aktive Positionen von Ajay K. Agrawal
| Unternehmen | Position | Beginn |
|---|---|---|
| Almac Sciences Group Ltd. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Ajay K. Agrawal
| Unternehmen | Position | Ende |
|---|---|---|
| IMMUPHARMA PLC | Direktor/Vorstandsmitglied | 23.10.2015 |
Navitas Life Sciences GmbH
 Navitas Life Sciences GmbH Miscellaneous Commercial ServicesCommercial Services Part of TAKE Solutions Ltd., Navitas Life Sciences GmbH is a technology-enabled clinical research organization (CRO) providing outsourced data science, regulatory & safety and full-service CRO services. The company is based in Frankfurt, Germany. The German company was founded in 2007 by Achuta Rao Prasanna Dodballapur. The CEO is Harikesavanallur R. Srinivasan. | Direktor/Vorstandsmitglied | - |
Xenetic Biosciences (UK) Ltd.
 Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Ausbildung von Ajay K. Agrawal
| University of Alberta | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| IMMUPHARMA PLC | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Xenetic Biosciences (UK) Ltd.
Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Health Technology |
| Almac Sciences Group Ltd. | |
Navitas Life Sciences GmbH
Navitas Life Sciences GmbH Miscellaneous Commercial ServicesCommercial Services Part of TAKE Solutions Ltd., Navitas Life Sciences GmbH is a technology-enabled clinical research organization (CRO) providing outsourced data science, regulatory & safety and full-service CRO services. The company is based in Frankfurt, Germany. The German company was founded in 2007 by Achuta Rao Prasanna Dodballapur. The CEO is Harikesavanallur R. Srinivasan. | Commercial Services |
